Lowest Price Guaranteed From USD 5,899
Published
June 2021
Pages
503
View Count
6349
Example Insights
Report Description
Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In 2020, the US FDA’s Center for Drug Evaluation and Research approved 35 small molecule drugs, representing 66% of the total number of new molecular entities (NMEs) clearing regulatory review in the same year. It is worth highlighting that the process of drug development, beginning from the discovery of a pharmacological lead to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase, actually make it into the clinical phase, and an even lesser number of product candidates enter the market. Therefore, to optimize on internal resource utilization and save costs, innovator companies in the pharmaceutical industry are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs).
Modern CROs offer a plethora of pharmaceutical discovery (such as target discovery & validation, hit identification (using strategies such as high-throughput screening, fragment-based screening, virtual screening, knowledge-based screening and DNA-encoded libraries), and lead generation / optimization) and product development related services, leveraging a variety of advanced technologies to cater to the evolving needs of sponsors / clients. As indicated earlier, engaging third party service providers offers both time and cost related benefits to drug / therapy developers. Currently, over 500 companies / organization claim to be actively providing contract research services for small molecule drugs. In the recent past, many of the service providers in this domain forged strategic alliances and / or acquired other players, in order to further enhance their respective service portfolios and thereby, consolidate their presence in the industry. The aforementioned developments may be attributed to the growing preference for one-stop-shops among sponsor companies, and the gradual acceptance of outsourcing as a viable and beneficial operating model. Based on prevalent trends and projections of how the pharmaceutical pipeline is likely to evolve over the coming years, we believe that demand for pharmaceutical CROs is going to grow at a steady pace. Consequently, the small molecule drug discovery and development services market is anticipated to witness consistent growth till 2030.
The "Pharmaceutical Contract Research Services Market, 2021-2030" report features an extensive study on contract service providers engaged in discovery, preclinical and clinical research of small molecule drugs. The study features in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report includes:
One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical CROs market over the coming decade. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] scale of operation (discovery services, preclinical services and clinical stage services), [B] target therapeutic area (cardiovascular disorder, dermatological disorders, infectious disorder, inflammatory disorder, neurological disorder, oncological disorder, ophthalmological disorder, respiratory disorder and other disorders) and [C] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.
All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the pharmaceutical CROs market in the mid to long term.
Chapter 3 provides a general introduction to the process of drug discovery and development. The chapter highlights the challenges associated with small molecule drug discovery along with a detailed discussion on the need for outsourcing within the pharmaceutical industry and guidelines for selecting the right service provider.
Chapter 4 provides a comprehensive overview of the global pharmaceutical services market, highlighting the contributions of over 500 CROs. It features a detailed assessment of the market, based on a number of relevant parameters, such as year of establishment, company size, scale of operation (discovery, preclinical and clinical), location of headquarters, types of services offered (target discovery & validation, hit identification, hit-to-lead and lead generation, lead optimization, bioanalytical studies, other preclinical services, clinical trials related services, consulting and regulatory affairs management), hit identification strategy used (high-throughput screening, fragment based screening, virtual screening (structure based virtual screening, ligand based virtual screening and unspecified virtual screening), knowledge based screening, DNA Encoded Library (DEL) based screening and others), type of business model (fee-for-service and full time equivalent) and target therapeutic area.
Chapter 5 provides detailed profiles of some of the key players that are active in the pharmaceutical contract research services market. Each profile presents a brief overview of the company, its financial information (if available), service portfolio and recent developments and an informed future outlook.
Chapter 6 features a comprehensive company competitiveness analysis, highlighting prominent pharmaceutical contract service providers based in North America, Europe, Asia-Pacific and Rest of the world, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (considering a company’s years of experience), and service strength (which takes into account the service offerings, scale of operation, hit identification strategies and subject specific agreements).
Chapter 7 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2018. It includes brief descriptions of the various partnership models (including acquisition, clinical trial, platform utilization, product development, research, research and development, service, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation and target therapeutic area. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 8 presents a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2018-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition and geographical location of the companies.
Chapter 9 presents an insightful market forecast analysis, highlighting the likely growth of the pharmaceutical CROs market till the year 2031. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] scale of operation (discovery services, preclinical services and clinical stage services), [B] target therapeutic area (cardiovascular disorder, dermatological disorder, infectious disorder, inflammatory disorder, neurological disorder, oncological disorder, ophthalmological disorder, respiratory disorder and other disorders) and [C] key geographical region (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).
Chapter 10 features a detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider in key geographical regions (US, Europe and Asia-Pacific). It presents estimated direct and indirect expenses taking into consideration close to 100 relevant parameters over a span of 20 years.
Chapter 11 features a case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered.
Chapter 12 features the transcript of the discussion(s) held with key stakeholder(s) in the industry.
Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Discovery and Validation
3.3.3. Hit Generation
3.3.3.1. High-Throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA-Encoded Libraries Screening
3.3.4. Hit-to-Lead and Lead Generation
3.3.5. Lead Optimization
3.4. Challenges Associated with Small Molecule Discovery
3.5. Need for Outsourcing Drug Discovery Operations
3.6 Guidelines for Selecting a Contract Research Service Provider
3.7. Concluding Remarks
4. PHARMACEUTICAL CONTRACT RESEARCH SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical Contract Research Service Providers: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Company Size and Scale of Operation
4.2.6. Analysis by Types of Services Offered
4.2.7. Analysis by Location of Headquarters and Types of Services Offered
4.2.8. Analysis by Hit Identification Strategy Used
4.2.9. Analysis by Type of Business Model
4.2.10. Analysis by Target Therapeutic Area
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Pharmaceutical Contract Research Service Providers in North America
5.2.1. Albany Molecular Research (AMRI)
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Service Portfolio
5.2.1.4. Recent Developments and Future Outlook
5.2.2. BioDuro
5.2.2.1. Company Overview
5.2.2.2. Service Portfolio
5.2.2.3. Recent Developments and Future Outlook
5.2.3. BOC Sciences
5.2.3.1. Company Overview
5.2.3.2. Service Portfolio
5.2.3.3. Recent Developments and Future Outlook
5.2.4. Catalent Pharma
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Service Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.5. Charles River Laboratories
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Service Portfolio
5.2.5.4. Recent Developments and Future Outlook
5.2.6. ChemDiv
5.2.6.1. Company Overview
5.2.6.2. Service Portfolio
5.2.6.3. Recent Developments and Future Outlook
5.2.7. Covance
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Service Portfolio
5.2.7.4. Recent Developments and Future Outlook
5.2.8. Medpace
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Service Portfolio
5.2.8.4. Recent Developments and Future Outlook
5.2.9. QPS
5.2.9.1. Company Overview
5.2.9.2. Service Portfolio
5.2.9.3. Recent Developments and Future Outlook
5.3. Pharmaceutical Contract Research Service Providers in Europe
5.3.1. Concept Life Sciences
5.3.1.1. Company Overview
5.3.1.2. Service Portfolio
5.3.1.3. Recent Developments and Future Outlook
5.3.2. Evotec
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Service Portfolio
5.3.2.4. Recent Developments and Future Outlook
5.4. Pharmaceutical Contract Research Service Providers in Asia-Pacific
5.4.1. ChemPartner
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Service Portfolio
5.4.1.4. Recent Developments and Future Outlook
5.4.2. Pharmaron
5.4.2.1. Company Overview
5.4.2.2. Service Portfolio
5.4.2.3. Recent Developments and Future Outlook
5.4.3. Syngene
5.4.3.1. Company Overview
5.4.3.2. Financial Information
5.4.3.3. Service Portfolio
5.4.3.4. Recent Developments and Future Outlook
5.4.4. Torrent Pharma
5.4.4.1. Company Overview
5.4.4.2. Financial Information
5.4.4.3. Service Portfolio
5.4.4.4. Recent Developments and Future Outlook
5.4.5. WuXi AppTec
5.4.5.1. Company Overview
5.4.5.2. Financial Information
5.4.5.3. Service Portfolio
5.4.5.4. Recent Developments and Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers
6.4.1. Pharmaceutical Contract Research Service Providers based in North America
6.4.2. Pharmaceutical Contract Research Service Providers based in Europe
6.4.3. Pharmaceutical Contract Research Service Providers based in Asia- Pacific and Rest of the World
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Target Therapeutic Area
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Regional Analysis
7.3.8.1. Intercontinental and Intracontinental Agreements
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Merger and Acquisition Models
8.3. Pharmaceutical Contract Research Service Providers: Mergers and Acquisitions
8.3.1. Analysis by Year of Acquisition
8.3.2. Analysis by Geography
8.3.3. Intercontinental and Intracontinental Deals
8.4. Analysis by Key Value Drivers
8.4.1. Mergers and Acquisitions: Analysis by Key Value Drivers
8.5. Valuation Analysis: Acquisition Deal Multiples
8.5.1. Prominent Acquirers: Analysis by Number of Acquisitions
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030
9.4. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030: Distribution by Scale of Operation
9.4.1. Global Pharmaceutical Contract Research Service Providers Market for Discovery Services, 2021-2030
9.4.2. Global Pharmaceutical Contract Research Service Providers Market for Preclinical Services, 2021-2030
9.4.3. Global Pharmaceutical Contract Research Service Providers Market for Clinical Services, 2021-2030
9.5. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030: Distribution by Target Therapeutic Area
9.5.1. Global Pharmaceutical Contract Research Service Providers Market for Oncological Disorders, 2021-2030
9.5.2. Global Pharmaceutical Contract Research Service Providers Market for Infectious Diseases, 2021-2030
9.5.3. Global Pharmaceutical Contract Research Service Providers Market for Neurological Disorders, 2021-2030
9.5.4. Global Pharmaceutical Contract Research Service Providers Market for Inflammatory Disorders, 2021-2030
9.5.5. Global Pharmaceutical Contract Research Service Providers Market for Cardiovascular Disorders, 2021-2030
9.5.6. Global Pharmaceutical Contract Research Service Providers Market for Dermatological Disorders, 2021-2030
9.5.7. Global Pharmaceutical Contract Research Service Providers Market for Ophthalmological Diseases, 2021-2030
9.5.8. Global Pharmaceutical Contract Research Service Providers Market for Respiratory Disorders, 2021-2030
9.5.9. Global Pharmaceutical Contract Research Service Providers Market for Other Disorders, 2021-2030
9.6. Global Pharmaceutical Contract Research Service Providers Market, 2021-2030: Distribution by Region
9.6.1. Pharmaceutical Contract Research Service Providers Market in North America, 2021-2030
9.6.2. Pharmaceutical Contract Research Service Providers Market in Europe, 2021-2030
9.6.3. Pharmaceutical Contract Research Service Providers Market in Asia-Pacific, 2021-2030
9.6.4. Pharmaceutical Contract Research Service Providers Market in Middle East, 2021-2030
9.6.5. Pharmaceutical Contract Research Service Providers Market in Latin America, 2021-2030
10. TOTAL COST OF OWNERSHIP IN PHARMACEUTICAL CONTRACT RESEARCH ORGANIZATION
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Output
11. CASE STUDY: BIOPHARMACEUTICAL CONTRACT RESEARCH SERVICES MARKET
11.1. Chapter Overview
11.2. Biopharmaceutical CROs: Overall Market Landscape
11.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
11.2.2. Analysis by Scale of Operation
11.3. Preclinical Biopharmaceutical CROs
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Location of Headquarters
11.3.4. Analysis by Type of Biologic
11.3.5. Analysis by Type of Services Offered
11.4. Clinical Biopharmaceutical CROs
11.4.1. Analysis by Year of Establishment
11.4.2. Analysis by Company Size
11.4.3. Analysis by Location of Headquarters
11.4.4. Analysis by Type of Biologics
11.4.5. Analysis by Type of Services Offered
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. ChemoGenics Biopharma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Francis X. Tavares, Founder and Chief Executive Officer
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
Figure 3.1 Drug Discovery and Development Pipeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Guidelines for Selecting a Contract Research Service Provider
Figure 4.1 Pharmaceutical Contract Research Service Providers: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical Contract Research Service Providers: Distribution by Company Size
Figure 4.3 Pharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Figure 4.4 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters
Figure 4.5 World Map Representation: Analysis by Geography
Figure 4.6 Pharmaceutical Contract Research Service Providers: Distribution by Company Size and Scale of Operation
Figure 4.7 Pharmaceutical Contract Research Service Providers: Distribution by Types of Services Offered
Figure 4.8 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters and Types of Services Offered
Figure 4.9 Pharmaceutical Contract Research Service Providers: Distribution by Hit Identification Strategy Used
Figure 4.10 Pharmaceutical Contract Research Service Providers: Distribution by Type of Business Model
Figure 4.11 Pharmaceutical Contract Research Service Providers: Distribution by Target Therapeutic Area
Figure 5.1 Catalent Pharma: Annual Revenues, 2016-9M 2021 (USD Billion)
Figure 5.2 Charles River Laboratories: Annual Revenues, 2016-3M 2021 (USD Billion)
Figure 5.3 Covance: Annual Revenues, 2016-3M 2021 (USD Billion)
Figure 5.4 Medpace: Annual Revenues, 2016-3M 2021 (USD Billion)
Figure 5.5 Evotec: Annual Revenues, 2016-3M 2021 (EUR Million)
Figure 5.6 Syngene: Annual Revenues, 2016-2021 (INR Billion)
Figure 5.7 Torrent Pharma: Annual Revenues, 2016-2021 (INR Million)
Figure 5.8 WuXi AppTec: Annual Revenues, 2017-3M 2021 (RMB Billion)
Figure 6.1 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers based in Asia Pacific and Rest of the World
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 7.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 7.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.8 Most Active Players: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Regional Distribution
Figure 7.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (2018- 2021)
Figure 8.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 8.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 8.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 8.5 Mergers and Acquisitions: Region-wise Distribution
Figure 8.6 Mergers and Acquisitions: Country-wise Distribution
Figure 8.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 8.8 Mergers and Acquisitions: Key Value Drivers
Figure 8.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 8.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 8.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Figure 9.1 Global Pharmaceutical Contract Research Services Market, 2021-2030 (USD Billion)
Figure 9.2 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 9.3 Global Pharmaceutical Contract Research Services Market for Discovery Services, 2021-2030 (USD Billion)
Figure 9.4 Global Pharmaceutical Contract Research Services Market for Preclinical Services, 2021-2030 (USD Billion)
Figure 9.5 Global Pharmaceutical Contract Research Services Market for Clinical Stage Services, 2021-2030 (USD Billion)
Figure 9.6 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Target Therapeutic Area (USD Billion)
Figure 9.7 Global Pharmaceutical Contract Research Services Market for Oncological Disorders, 2021-2030 (USD Billion)
Figure 9.8 Global Pharmaceutical Contract Research Services Market for Infectious Diseases, 2021-2030 (USD Billion)
Figure 9.9 Global Pharmaceutical Contract Research Services Market for Neurological Disorders, 2021-2030 (USD Billion)
Figure 9.10 Global Pharmaceutical Contract Research Services Market for Inflammatory Disorders, 2021-2030 (USD Billion)
Figure 9.11 Global Pharmaceutical Contract Research Services Market for Cardiovascular Disorders, 2021-2030 (USD Billion)
Figure 9.12 Global Pharmaceutical Contract Research Services Market for Dermatological Disorders, 2021-2030 (USD Billion)
Figure 9.13 Global Pharmaceutical Contract Research Services Market for Ophthalmological Diseases, 2021-2030 (USD Billion)
Figure 9.14 Global Pharmaceutical Contract Research Services Market for Respiratory Disorders, 2021-2030 (USD Billion)
Figure 9.15 Global Pharmaceutical Contract Research Services Market for Other Disorders, 2021-2030 (USD Billion)
Figure 9.16 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Geography (USD Billion)
Figure 9.17 Global Pharmaceutical Contract Research Services Market in North America, 2021-2030 (USD Billion)
Figure 9.18 Global Pharmaceutical Contract Research Services Market in Europe, 2021-2030 (USD Billion)
Figure 9.19 Global Pharmaceutical Contract Research Services Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 9.20 Global Pharmaceutical Contract Research Services Market in Middle East and North Africa, 2021-2030 (USD Billion)
Figure 9.21 Global Pharmaceutical Contract Research Services Market in Latin America, 2021-2030 (USD Billion)
Figure 10.1 Total Cost of Ownership in Pharmaceutical Contract Research Organization: Output
Figure 11.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 11.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Figure 11.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Figure 11.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Figure 11.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Figure 11.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Figure 11.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Figure 11.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Figure 11.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 11.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Figure 11.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
Figure 11.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Figure 11.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Figure 11.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Figure 11.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Figure 11.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Partnerships and Collaborations
Figure 13.3 Concluding Remarks: Mergers and Acquisitions
Figure 13.4 Concluding Remarks: Market Forecast
Figure 13.5 Concluding Remarks: Total Cost of Ownership in Pharmaceutical Contract Research Organization
Table 4.1 Pharmaceutical Contract Research Service Providers: List of Industry Players
Table 4.2 Pharmaceutical Contract Research Service Providers: Information on Scale of Operation
Table 4.3 Pharmaceutical Contract Research Service Providers: Information on Types of Services Offered
Table 4.4 Pharmaceutical Contract Research Service Providers: Information on Hit Identification Strategy Used
Table 4.5 Pharmaceutical Contract Research Service Providers: Information on Type of Business Model
Table 4.6 Pharmaceutical Contract Research Service Providers: Information on Type of Business Model
Table 4.7 Pharmaceutical Contract Research Service Providers: Information on Target Therapeutic Area
Table 5.1 Pharmaceutical Contract Research Service Providers: List of Profiled Companies
Table 5.2 AMRI: Company Overview
Table 5.3 AMRI: Service Portfolio
Table 5.4 AMRI: Recent Developments and Future Outlook
Table 5.5 BioDuro: Company Overview
Table 5.6 BioDuro: Service Portfolio
Table 5.7 BioDuro: Recent Developments and Future Outlook
Table 5.8 BOC Sciences: Company Overview
Table 5.9 BOC Sciences: Service Portfolio
Table 5.10 BOC Sciences: Recent Developments and Future Outlook
Table 5.11 Catalent Pharma: Company Overview
Table 5.12 Catalent Pharma: Service Portfolio
Table 5.13 Catalent Pharma: Recent Developments and Future Outlook
Table 5.14 Charles River Laboratories: Company Overview
Table 5.15 Charles River Laboratories: Service Portfolio
Table 5.16 Charles River Laboratories: Recent Developments and Future Outlook
Table 5.17 ChemDiv: Company Overview
Table 5.18 ChemDiv: Service Portfolio
Table 5.19 ChemDiv: Recent Developments and Future Outlook
Table 5.20 Covance: Company Overview
Table 5.21 Covance: Service Portfolio
Table 5.22 Covance: Recent Developments and Future Outlook
Table 5.23 Medpace: Company Overview
Table 5.24 Medpace: Service Portfolio
Table 5.25 Medpace: Recent Developments and Future Outlook
Table 5.26 QPS: Company Overview
Table 5.27 QPS: Service Portfolio
Table 5.28 QPS: Recent Developments and Future Outlook
Table 5.29 Concept Life Sciences: Company Overview
Table 5.30 Concept Life Sciences: Service Portfolio
Table 5.31 Concept Life Sciences: Recent Developments and Future Outlook
Table 5.32 Evotec: Company Overview
Table 5.33 Evotec: Service Portfolio
Table 5.34 Evotec: Recent Developments and Future Outlook
Table 5.35 ChemPartner: Company Overview
Table 5.36 ChemPartner: Service Portfolio
Table 5.37 ChemPartner: Recent Developments and Future Outlook
Table 5.38 Pharmaron: Company Overview
Table 5.39 Pharmaron: Service Portfolio
Table 5.40 Pharmaron: Recent Developments and Future Outlook
Table 5.41 Syngene: Company Overview
Table 5.42 Syngene: Service Portfolio
Table 5.43 Syngene: Recent Developments and Future Outlook
Table 5.44 Torrent Pharma: Company Overview
Table 5.45 Torrent Pharma: Service Portfolio
Table 5.46 Torrent Pharma: Recent Developments and Future Outlook
Table 5.47 WuXi AppTec: Company Overview
Table 5.48 WuXi AppTec: Service Portfolio
Table 5.49 WuXi AppTec: Recent Developments and Future Outlook
Table 7.1 Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
Table 8.1 Mergers and Acquisitions: List of Mergers / Acquisitions, 2018-2021
Table 8.2 Mergers and Acquisitions: Information on Key Value Drivers, 2018-2021
Table 8.3 Mergers and Acquisitions: Deal Multiples, 2018-2021
Table 11.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
Table 11.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
Table 12.1 ChemoGenics Biopharma: Key Highlights
Table 14.1 Pharmaceutical Contract Research Service Providers: Distribution by Year of Establishment
Table 14.2 Pharmaceutical Contract Research Service Providers: Distribution by Scale of Operation
Table 14.3 Pharmaceutical Contract Research Service Providers: Distribution by Company Size
Table 14.4 Pharmaceutical Contract Research Service Providers: Distribution by Location of Headquarters
Table 14.5 World Map Representation: Analysis by Geography
Table 14.6 Pharmaceutical Contract Research Service Providers: Distribution by Company Size and Scale of Operation
Table 14.7 Pharmaceutical Contract Research Service Providers: Distribution by Types of Services Offered
Table 14.9 Pharmaceutical Contract Research Service Providers: Distribution by Hit Identification Strategy Used
Table 14.10 Pharmaceutical Contract Research Service Providers: Distribution by Type of Business Model
Table 14.11 Pharmaceutical Contract Research Service Providers: Distribution by Target Therapeutic Area
Table 14.12 Catalent Pharma: Annual Revenues, 2016-9M 2021 (USD Billion)
Table 14.13 Charles River Laboratories: Annual Revenues, 2016-3M 2021 (USD Billion)
Table 14.14 Covance: Annual Revenues, 2016-3M 2021 (USD Billion)
Table 14.15 Medpace: Annual Revenues, 2016-3M 2021 (USD Billion)
Table 14.16 Evotec: Annual Revenues, 2016-3M 2021 (EUR Million)
Table 14.17 Syngene: Annual Revenues, 2016-2021 (INR Billion)
Table 14.18 Torrent Pharma: Annual Revenues, 2016-2021 (INR Million)
Table 14.19 WuXi AppTec: Annual Revenues, 2017-3M 2021 (RMB Billion)
Table 14.20 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2021
Table 14.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.22 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.23 Partnerships and Collaborations: Distribution by Scale of Operation
Table 14.24 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 14.25 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.27 Most Active Players: Distribution by Number of Partnerships
Table 14.28 Partnerships and Collaborations: Regional Distribution
Table 14.29 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.30 Mergers and Acquisitions: List of Mergers / Acquisitions, 2016 - 2020
Table 14.31 Mergers and Acquisitions: Information on Key Value Drivers, 2016- 2020
Table 14.32 Mergers and Acquisitions: Deal Multiples, 2016- 2020
Table 14.33 Global Pharmaceutical Contract Research Services Market, 2021-2030 (USD Billion)
Table 14.34 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 14.35 Global Pharmaceutical Contract Research Services Market for Discovery Services, 2021-2030 (USD Billion)
Table 14.36 Global Pharmaceutical Contract Research Services Market for Preclinical Services, 2021-2030 (USD Billion)
Table 14.37 Global Pharmaceutical Contract Research Services Market for Clinical Stage Services, 2021-2030 (USD Billion)
Table 14.38 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Target Therapeutic Area (USD Billion)
Table 14.39 Global Pharmaceutical Contract Research Services Market for Oncological Disorders, 2021-2030 (USD Billion)
Table 14.40 Global Pharmaceutical Contract Research Services Market for Infectious Diseases, 2021-2030 (USD Billion)
Table 14.41 Global Pharmaceutical Contract Research Services Market for Neurological Disorders, 2021-2030 (USD Billion)
Table 14.42 Global Pharmaceutical Contract Research Services Market for Inflammatory Disorders, 2021-2030 (USD Billion)
Table 14.43 Global Pharmaceutical Contract Research Services Market for Cardiovascular Disorders, 2021-2030 (USD Billion)
Table 14.44 Global Pharmaceutical Contract Research Services Market for Dermatological Disorders, 2021-2030 (USD Billion)
Table 14.45 Global Pharmaceutical Contract Research Services Market for Ophthalmological Disorders, 2021-2030 (USD Billion)
Table 14.46 Global Pharmaceutical Contract Research Services Market for Respiratory Disorders, 2021-2030 (USD Billion)
Table 14.47 Global Pharmaceutical Contract Research Services Market for Other Disorders, 2021-2030 (USD Billion)
Table 14.48 Global Pharmaceutical Contract Research Services Market, 2021-2030: Distribution by Geography (USD Billion)
Table 14.49 Global Pharmaceutical Contract Research Services Market in North America, 2021-2030 (USD Billion)
Table 14.50 Global Pharmaceutical Contract Research Services Market in Europe, 2021-2030 (USD Billion)
Table 14.51 Global Pharmaceutical Contract Research Services Market in Asia-Pacific, 2021-2030 (USD Billion)
Table 14.52 Global Pharmaceutical Contract Research Services Market in Middle East and North Africa, 2021-2030 (USD Billion)
Table 14.53 Global Pharmaceutical Contract Research Services Market in Latin America, 2021-2030 (USD Billion)
Table 14.54 Total Cost of Ownership in Pharmaceutical Contract Research Organization: Output
Table 14.55 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 14.56 Biopharmaceutical CROs: Distribution by Scale of Operation
Table 14.57 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Table 14.58 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Table 14.59 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Table 14.60 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Table 14.61 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Table 14.62 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Table 14.63 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Table 14.64 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Table 14.65 Biopharmaceutical Clinical CROs: Distribution by Company Size
Table 14.66 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Table 14.67 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Table 14.68 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Table 14.69 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Table 14.70 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered